Benitec Biopharma announces interim Phase 1b/2a study of BB-301

Benitec Biopharma (BNTC) announced “promising” interim clinical results from the BB-301 Phase 1b/2a first-in-human study evaluating low dose and high dose BB-301 treatment for Oculopharyngeal Muscular Dystrophy with moderate dysphagia. Interim and long-term clinical results for patients enrolled into Cohort 1, and interim clinical results for the first patient enrolled into Cohort 2 in the ongoing clinical trial will be presented as a late-breaking poster presentation at the Muscular Dystrophy Association, MDA, Clinical and Scientific Conference, in Orlando, Florida on March 9, 2026. “We are strongly encouraged by the 100% response rate and the depth and durability of the responses that have been observed for all patients treated with BB-301 to date,” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec. “We are incredibly excited to share these interim clinical results which demonstrate positive, clinically meaningful improvements across the most critical radiographic, functional, and patient-reported assessments of swallowing function. With no currently approved treatments for OPMD patients, the results presented today represent an important step towards the management of the unmet medical need that exists in the OPMD community.”